

Supplementary

Table 1. Characteristics of AML patients whose BM samples were treated with ARRY-520 for colony forming assay

Blast %	Cytogenetics	Treatment and Responses
72	46,XX[20]	untreated at sampling; later treated with 5-AZA+VA+ATRA, resistant; treated with Ara-C, died
92	46,XX,t(9;11)(p22;q23)[20]	untreated at sampling; treated with IA+ZARNESTRA, died
61	46,XX[20]	untreated at sampling; later treated with IDA+HDAC, achieved CR and then relapsed; resistant to various therapies including Mitoxantrone+etoposide+Ara C, sorafenib, decitabine+Mylotarg, and sorafenib+idarubicin+Ara C
76	46,XY[20]	untreated at sampling; later treated with IDA+HDAC, achieved CR then relapsed; disease progressed on sapacitabine
81	45,XY,t(3;3)(q21;q26.2),-7[17]; 45,idem[cp3]	resistant to 3+7 followed by 2+5 treatment; no response to imatinib; resistant to mitoxantrone and etoposide; after sampling, treated with sapacitabine, TCN-PM, Mylotarg+Ara-C+decitabine and resistant to all